NLS PHARMACEUTICS LTD's ticker is NLSPW and the CUSIP is H57830111. A total of 6 filers reported holding NLS PHARMACEUTICS LTD in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $3,010 | -38.6% | 100,000 | 0.0% | 0.00% | – |
| Q1 2024 | $4,900 | -12.7% | 100,000 | 0.0% | 0.00% | – |
| Q4 2023 | $5,610 | -73.3% | 100,000 | -50.0% | 0.00% | – |
| Q3 2023 | $21,040 | +106.3% | 200,000 | +100.0% | 0.00% | – |
| Q2 2023 | $10,200 | -66.0% | 100,000 | -50.0% | 0.00% | – |
| Q1 2023 | $30,000 | +8.2% | 200,000 | +100.0% | 0.00% | – |
| Q4 2022 | $27,720 | +10.9% | 100,000 | 0.0% | 0.00% | – |
| Q3 2022 | $25,000 | +108.3% | 100,000 | 0.0% | 0.00% | – |
| Q2 2022 | $12,000 | -68.4% | 100,000 | 0.0% | 0.00% | -100.0% |
| Q1 2022 | $38,000 | -77.0% | 100,000 | -50.0% | 0.00% | -50.0% |
| Q4 2021 | $165,000 | +7.1% | 200,000 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $154,000 | -19.8% | 200,000 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $192,000 | +1.1% | 200,000 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $190,000 | – | 200,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Altium Capital Management LP | 200,000 | $6,900 | 0.00% |
| ARMISTICE CAPITAL, LLC | 500,000 | $17,250 | 0.00% |
| CLEAR STREET LLC | 8,271 | $0 | 0.00% |
| Hudson Bay Capital Management LP | 100,000 | $3,010 | 0.00% |
| Citadel Advisors | 16,008 | $482 | 0.00% |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 12,221 | $368 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |